Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

Clinical genitourinary cancer - 1 Aug 2020

Bacon Jack V W, Annala Matti, Soleimani Maryam, Lavoie Jean-Michel, So Alan, Gleave Martin E, Fazli Ladan, Wang Gang, Chi Kim N, Kollmannsberger Christian K, Wyatt Alexander W, Nappi Lucia

Abstract excerpt

BACKGROUND: There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. MATERIALS AND METHODS: Whole blood was collected from 55 patients with metastatic RCC. Plasma cfDNA and leukocyte DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Clonal Hematopoiesis

Share to Follow-Up Studies

Share to High-Throughput Nucleotide Sequencing

Share to Kidney Neoplasms

Share to Survival Rate

Source

Identifiers

PMID: 32046920
DOI: 10.1016/j.clgc.2019.12.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.PMID 32046920Read ↗

Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database.Semantic proximity Read ↗

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.Semantic proximity Read ↗

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.Semantic proximity Read ↗

Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.Semantic proximity Read ↗

Detecting circulating tumor DNA in renal cancer: An open challengeSemantic proximity Read ↗

Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinomaSemantic proximity Read ↗

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.Semantic proximity Read ↗

Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinomaSemantic proximity Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

The amount of circulating DNA and the presence of TP53 mutations in plasma predict clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsSemantic proximity Read ↗

Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.